Spark Therapeutics Inc

Latest Spark Therapeutics Inc News and Updates

  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    A Look at Spark’s Potential Revenue Contribution to Roche Holdings

    Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///dna _
    Healthcare

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

    By Mike Benson
  • uploads///cells _
    Company & Industry Overviews

    Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018

    Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.

    By Kenneth Smith
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.